Myxoma vims

Turner PC, Sancho MC, Ihoennes SR et al. Myxoma vims serp-2 is a weak inhibitor of granzyme B and intcrleukin-lbeta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus— infected cells. J Virol 1999 73 6394-6404. 

A recent study reports the release profile of the Serp-1 proteinase from PVA-C [65]. Serp-1 is a serine proteinase inhibitor (serpin) secreted by the myxoma vims and is a potential new therapeutic for cardiovascular diseases. It has exhibited antiinflammatory activity through the modulation of immune cell responses [66]. The release profile of this protein in a buffer medium is typical of that of a diffusion controlled process. However, it is interesting to know that the release rate of Serp-1 and its final release level attained differ in human blood and in buffer. The release rate is twice as fast and in half of the time in blood than in buffer. The final release level is complete in blood and appears to level off at around 50% in buffer. It was suggested that there may be a difference in behavior between the two release media, which is important to consider because human whole blood represents a more realistic setting of the physiological environment in arteries. It is also possible that interaction between PVA-C and blood components play a role in determining the ultimate release rate (Fig. 9a, b) [65]. 

---